Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab

ConclusionThe results suggest that starting natalizumab early, during active inflammatory disease results in a more favorable outcome. When taking into account early inflammation and the impact of natalizumab on disease activity during the initial treatment phase, a higher than expected proportion of patients showed disability progression.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research